Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulised Liposomal Amphotericin B for Invasive Pulmonary Aspergillosis
NCT04267497Phase 1Completed
- Start
- Oct 2019
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial in Invasive Pulmonary Aspergillosis (IPA) comparing Nebulized Amphotericin B with Nebulized Placebo (2 arms). Primary endpoints: Reduction of >20% of post-nebulized FVC at 6 weeks and Reduction of >20% of post-nebulized FEV1 at 6 weeks. Started Oct 2019; status: completed.
02
Drugs
amphotericin b
03
Conditions
Invasive Pulmonary Aspergillosis (IPA)
Beyond the preview
Go deeper on NCT04267497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04267497.